Mafosfamide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mafosfamide
Skeletal formula
Ball-and-stick model
Names
IUPAC name
2-{(2-[bis(2-chloroethyl)amino]-2-oxido-1,3,2-oxazaphosphinan-4-yl}thio)ethanesulfonic acid
Other names
2-{[2-[bis(2-chloroethyl)amino]-2-oxo-1-oxa-3-aza-2λ5-phosphacyclohex-4-yl}sulfanyl]ethanesulfonic acid
Identifiers
88859-04-5 N
ChemSpider 16736958 YesY
Jmol-3D images Image
MeSH Mafosfamide
PubChem 104746
Properties
C9H19Cl2N2O5PS2
Molar mass 401.269 g/mol
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 N verify (what isYesY/N?)
Infobox references

Mafosfamide (INN) is an oxazaphosphorine (cyclophosphamide-like) alkylating agent under investigation as a chemotherapeutic. It is metabolized by cytochrome P450 into 4-Hydroxycyclophosphamide, which is then converted into aldophosphamide, which, in turn yields the cytotoxic metabolites phosphoramide mustard and acrolein.[1]

Several Phase I trials have been completed.[2][3]

References[edit]

  1. ^ Ludeman SM. The chemistry of the metabolites of cyclophosphamide. Curr Pharm Des. 1999 Aug;5(8):627-43. PMID 10469895
  2. ^ "Intrathecal Mafosfamide". ClinicalTrials.gov. U.S. National Institutes of Health. August 21, 2006. Retrieved 2007-07-13.  ClinicalTrials.gov Identifier NCT00062881.
  3. ^ "Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors". ClinicalTrials.gov. U.S. National Institutes of Health. February 20, 2007. Retrieved 2007-07-13.  ClinicalTrials.gov Identifier NCT00031928.